Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

buir.contributor.authorİşbilen, Murat
dc.citation.issueNumber1
dc.citation.volumeNumber14
dc.contributor.authorHill, R.
dc.contributor.authorMadureira, P. A.
dc.contributor.authorFerreira, B.
dc.contributor.authorBaptista, I.
dc.contributor.authorMachado, S.
dc.contributor.authorColaҫo, L.
dc.contributor.authordos Santos, M.
dc.contributor.authorLiu, N.
dc.contributor.authorDopazo, A.
dc.contributor.authorUgurel, S.
dc.contributor.authorAdrienn, A.
dc.contributor.authorKiss-Toth, E.
dc.contributor.authorİşbilen, Murat
dc.contributor.authorGure, A. O.
dc.contributor.authorLink, W.
dc.date.accessioned2024-03-21T15:28:36Z
dc.date.available2024-03-21T15:28:36Z
dc.date.issued2023-07-19
dc.description.abstractRetraction to: Nature Communications, published online 09 March 2017 The authors have retracted this article as it has come to their attention that several images were inappropriately processed and duplicated in multiple figures. In particular, the data were duplicated, and in some cases inverted, across several panels in Figures 2c, 2b, 3d and Supplementary Figure 5. Erroneous data were also included in Figure 2e, Supplementary Figure 1 and Supplementary Figure 8. We apologize to the scientific community for any confusion this article may have caused. Richard Hill, Patricia Madureira, Bibiana I. Ferreira, Susana Machado, Ana Dopazo, Selma Ugurel, Endre Kiss-Toth, Murat isbilen and Wolfgang Link agree with this retraction. Inês Baptista, Laura Colaço, Marta dos Santos, Ningshu Liu, Angyal Adrienn and Ali O. Gure have not responded to correspondence from the Publisher about this retraction. © 2023, The Author(s).
dc.description.provenanceMade available in DSpace on 2024-03-21T15:28:36Z (GMT). No. of bitstreams: 1 Retraction_note_TRIB2_confers_resistance_to_anti-cancer_therapy_by_activating_the_serinethreonine_protein_kinase_AKT.pdf: 168981 bytes, checksum: 90a9a2cb6acc69c1281f52da6d657428 (MD5) Previous issue date: 2023-07-19en
dc.identifier.doi10.1038/s41467-023-40050-1
dc.identifier.eissn2041-1723
dc.identifier.urihttps://hdl.handle.net/11693/115051
dc.publisherNature Research
dc.relation.isversionofhttps://dx.doi.org/10.1038/s41467-023-40050-1
dc.source.titleNature Communications
dc.titleRetraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
dc.typeErratum

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Retraction_note_TRIB2_confers_resistance_to_anti-cancer_therapy_by_activating_the_serinethreonine_protein_kinase_AKT.pdf
Size:
165.02 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.01 KB
Format:
Item-specific license agreed upon to submission
Description: